Breaking News

Amgen to Acquire KAI Pharmaceuticals

Gains lead product candidate, KAI-4169

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Amgen will acquire KAI Pharmaceuticals, a privately held pharmaceutical company based in South San Francisco, for $315 million in cash. KAI’s lead product candidate, KAI-4169, is a novel drug being studied for the treatment of secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease (CKD) who are on dialysis. Amgen will acquire worldwide rights to the drug, excluding Japan. In connection with the agreement, Amgen has provided a loan for Phase III development for KAI-4169 pri...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters